EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Predicting abiraterone efficacy in advanced prostate cancer: Insights from marker of proliferation Ki67

Fengnian Zhao, Jinge Zhao, Xinyuan Wei, Yifu Shi, Nanwei Xu, Sha Zhu, Junru Chen, Guangxi Sun, Jindong Dai, Zhipeng Wang, Xingming Zhang, Jiayu Liang und 8 weitere

The Prostate · 2024

DOI: 10.1002/pros.24710 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Prostate, 2024. Verfasst von Fengnian Zhao und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China. Hauptthemen laut MEDLINE: Ki-67 Antigen, Androstenes, Prostatic Neoplasms, Biomarkers, Tumor. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, 82172785, 1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

KI67 is a well‐known biomarker reflecting cell proliferation. We aim to elucidate the predictive role of KI67 in the efficacy of abiraterone for patients with advanced prostate cancer (PCa).

Methods

Clinicopathological data of 152 men with metastatic PCa, who received abiraterone therapy were retrospectively collected. The KI67 positivity was examined by immunohistochemistry using the prostate biopsy specimen. The predictive value of KI67 on the therapeutic efficacy of abiraterone was explored using Kaplan–Meier curve and Cox regression analysis. The endpoints included prostate‐specific antigen (PSA) progression‐free survival (PSA‐PFS), radiographic PFS (rPFS), and overall survival (OS).

Results

In total, 85/152 (55.9%) and 67/152 (44.1%) cases, respectively, received abiraterone at metastatic hormone‐sensitive (mHSPC) and castration‐resistant PCa (mCRPC) stage. The median KI67 positivity was 20% (interquartile range: 10%–30%). Overall, KI67 rate was not correlated with PSA response. Notably, an elevated KI67‐positive rate strongly correlated with unfavorable abiraterone efficacy, with KI67 ≥ 30% and KI67 ≥ 20% identified as the optimal cutoffs for prognosis differentiation in mHSPC (median PSA‐PFS: 11.43 Mo vs. 26.43 Mo, p < 0.001; median rPFS: 16.63 Mo vs. 31.90 Mo, p = 0.003; median OS: 21.77 Mo vs. not reach, p = 0.005) and mCRPC (median PSA‐PFS: 7.17 Mo vs. 12.20 Mo, p = 0.029; median rPFS: 11.67 Mo vs. 16.47 Mo, p = 0.012; median OS: 21.67 Mo vs. not reach, p = 0.073) patients, respectively. Multivariate analysis supported the independent predictive value of KI67 on abiraterone efficacy. In subgroup analysis, an elevated KI67 expression was consistently associated with unfavorable outcomes in the majority of subgroups. Furthermore, data from another cohort of 79 PCa patients with RNA information showed that those with KI67 RNA levels above the median had a significantly shorter OS than those below the median (17.71 vs. 30.72 Mo, p = 0.035).

Conclusions

This study highlights KI67 positivity in prostate biopsy as a strong predictor of abiraterone efficacy in advanced PCa. These insights will assist clinicians in anticipating clinical outcomes and refining treatment decisions for PCa patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ki-67 AntigenAndrostenesProstatic NeoplasmsBiomarkers, TumorHumansMaleAgedRetrospective StudiesMiddle AgedCell ProliferationProstate-Specific AntigenProstatic Neoplasms, Castration-ResistantTreatment OutcomePredictive Value of TestsProgression-Free SurvivalAged, 80 and overAntineoplastic Agents

Stichwörter der Autor:innen

KI67abirateroneprostate cancertherapeutic effect

Substanzen

Ki-67 AntigenabirateroneAndrostenesBiomarkers, TumorProstate-Specific AntigenAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.
  • Department of Pathology, West China Hospital, Sichuan University, Chengdu, China.

ORCID-Profile: Pengfei Shen, Ni Chen, Hao Zeng

Förderung

  • National Natural Science Foundation of China
  • 82172785
  • 1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University
  • Science and Technology Support Program of Sichuan Province
  • Clinical and Translational Medicine Research Project, Chinese Academy of Medical Sciences
  • Beijing Bethune Charitable Foundation
  • Postdoctoral Research and Development Fund of West China Hospital of Sichuan University

Zitieren

APA

Zhao, F., Zhao, J., Wei, X., Shi, Y., Xu, N., Zhu, S., Chen, J., Sun, G., Dai, J., Wang, Z., Zhang, X., Liang, J., Hu, X., Liu, H., Zhao, J., Liu, Z., Nie, L., Shen, P., Chen, N., & Zeng, H. (2024). Predicting abiraterone efficacy in advanced prostate cancer: Insights from marker of proliferation Ki67. The Prostate. https://doi.org/10.1002/pros.24710

Vancouver

Zhao F, Zhao J, Wei X, Shi Y, Xu N, Zhu S, et al. Predicting abiraterone efficacy in advanced prostate cancer: Insights from marker of proliferation Ki67. The Prostate. 2024. doi:10.1002/pros.24710

BibTeX
@article{Zhao2024,
  author = {Zhao, Fengnian and Zhao, Jinge and Wei, Xinyuan and Shi, Yifu and Xu, Nanwei and Zhu, Sha and Chen, Junru and Sun, Guangxi and Dai, Jindong and Wang, Zhipeng and Zhang, Xingming and Liang, Jiayu and Hu, Xu and Liu, Haoyang and Zhao, Junjie and Liu, Zhenhua and Nie, Ling and Shen, Pengfei and Chen, Ni and Zeng, Hao},
  title = {Predicting abiraterone efficacy in advanced prostate cancer: Insights from marker of proliferation Ki67},
  journal = {The Prostate},
  year = {2024},
  doi = {10.1002/pros.24710}
}
Kostenlos starten →